Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus paclitaxel and cisplatin for persistent, recurrent, or metastatic cervical cancer
ChiCTR1900028540Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, paclitaxel and cisplatin in Cervical Cancer (CC), sponsored by Peking University Cancer Hospital & Institute. Primary endpoints: Objective response rate and Safety and tolerability. Started Oct 2019; status: recruiting.
02
Drugs
sintilimabpaclitaxelcisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR1900028540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028540.